Format

Send to

Choose Destination
Brain. 2016 Apr;139(Pt 4):1226-36. doi: 10.1093/brain/aww015. Epub 2016 Mar 2.

Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography.

Author information

1
Clinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University, Sweden Department of Neurology, Skåne University Hospital, Sweden sebastian.palmqvist@med.lu.se oskar.hansson@med.lu.se.
2
Clinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University, Sweden Memory Clinic, Skåne University Hospital, Sweden.
3
Clinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University, Sweden Memory Clinic, Skåne University Hospital, Sweden sebastian.palmqvist@med.lu.se oskar.hansson@med.lu.se.

Abstract

Cerebral accumulation of amyloid-β is thought to be the starting mechanism in Alzheimer's disease. Amyloid-β can be detected by analysis of cerebrospinal fluid amyloid-β42 or amyloid positron emission tomography, but it is unknown if any of the methods can identify an abnormal amyloid accumulation prior to the other. Our aim was to determine whether cerebrospinal fluid amyloid-β42 change before amyloid PET during preclinical stages of Alzheimer's disease. We included 437 non-demented subjects from the prospective, longitudinal Alzheimer's Disease Neuroimaging Initiative (ADNI) study. All underwent (18)F-florbetapir positron emission tomography and cerebrospinal fluid amyloid-β42 analysis at baseline and at least one additional positron emission tomography after a mean follow-up of 2.1 years (range 1.1-4.4 years). Group classifications were based on normal and abnormal cerebrospinal fluid and positron emission tomography results at baseline. We found that cases with isolated abnormal cerebrospinal fluid amyloid-β and normal positron emission tomography at baseline accumulated amyloid with a mean rate of 1.2%/year, which was similar to the rate in cases with both abnormal cerebrospinal fluid and positron emission tomography (1.2%/year, P = 0.86). The mean accumulation rate of those with isolated abnormal cerebrospinal fluid was more than three times that of those with both normal cerebrospinal fluid and positron emission tomography (0.35%/year, P = 0.018). The group differences were similar when analysing yearly change in standardized uptake value ratio of florbetapir instead of percentage change. Those with both abnormal cerebrospinal fluid and positron emission tomography deteriorated more in memory and hippocampal volume compared with the other groups (P < 0.001), indicating that they were closer to Alzheimer's disease dementia. The results were replicated after adjustments of different factors and when using different cut-offs for amyloid-β abnormality including a positron emission tomography classification based on the florbetapir uptake in regions where the initial amyloid-β accumulation occurs in Alzheimer's disease. This is the first study to show that individuals who have abnormal cerebrospinal amyloid-β42 but normal amyloid-β positron emission tomography have an increased cortical amyloid-β accumulation rate similar to those with both abnormal cerebrospinal fluid and positron emission tomography and higher rate than subjects where both modalities are normal. The results indicate that cerebrospinal fluid amyloid-β42 becomes abnormal in the earliest stages of Alzheimer's disease, before amyloid positron emission tomography and before neurodegeneration starts.

KEYWORDS:

Alzheimer’s disease; CSF Aβ42; PET; amyloid-β; florbetapir

PMID:
26936941
PMCID:
PMC4806222
DOI:
10.1093/brain/aww015
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center